Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment

Pancreas

Volumn 39, Issue 5, 2010, Pages 595-603

  Toomey, Desmond P ^a   Manahan, Ellen ^a   McKeown, Ciara ^a   Rogers, Annamarie ^a   McMillan, Helen ^b   Geary, Michael ^b   Conlon, Kevin C ^a   Murphy, Joseph F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ROTUNDA HOSPITAL   (Ireland)

Author keywords

angiogenesis; celecoxib; COX 2; NSAIDs; pancreatic cancer; VEGF

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANGIOGENESIS; ARTICLE; CELL VIABILITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; UMBILICAL VEIN; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77954093560     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181c6575d     Document Type: Article

References (53)

1. The National Cancer Registry of Ireland. Available at: www.ncri.ie. Accessed December 12, 2008.
2. Baxter NN, Whitson BA, Tuttle TM. Trends in treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320-1326.
3. Jemal A, Murray T, Samuels A, et al. Cancer Statistics 2003. CA Cancer J Clin. 2003;53:5-26.
4. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
5. National Cancer Registry of Ireland 2006. Cancer in Ireland 1994-2005, a summary. Available at: www.ncri.ie. Accessed October 13, 2008.
6. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasia and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91: 333-338.
7. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by non steroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356-4362.
8. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990.
9. Yip-Schneider MT, Barnard D, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-146.
10. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55:115-122.
11. 2. Oncology. 2005;69(suppl 1):28-32.
12. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840-2855.
13. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rational and promise. Cancer Cell. 2003;4:431-436.
14. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol. 2005;2:202-210.
15. Matsubayashi H, Infante J, Winter J, et al. Tumour COX-2 expression and prognosis of patients with resectable pancreatic cancer [e-pub ahead of print]. Cancer Biol Ther. 2007;6(10):1569-1575.
16. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase-2 gene expression correlates with tumour angiogenesis in human colorectal cancer. Gastroenterology. 2001;121:1339-1347.
17. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumour angiogenesis and metastasis. Neoplasia. 2001;3:53-61.
18. Kim H-S, Youm H-R, Lee J-S, et al. Correlation between cyclooxygenase-2 and tumour angiogenesis in non small cell lung cancer. Lung Cancer. 2003;42:163-170.
19. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumour neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6: 4064-4068.
20. Shi H, Xu J-M, Hu N-Z, et al. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9:1421-1426.
21. McMahon G. VEGF receptor signalling in tumour angiogenesis. Oncologist. 2000;5:3-10.
22. Pandya NM, Dhalla NS, Santani DD. Angiogenesis - a new target for future therapy. Vasc Pharmacol. 2006;44:265-274.
23. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
24. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777-794.
25. Dermond O, Ruegg C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resist Updat. 2001;4:314-321.
26. Jones MK, Szabo IL, Kawanaka H, et al. Von Hippel-Lindau tumour suppressor and HIF-1alpha: new targets of NSAID inhibition of hypoxia induced angiogenesis. FASEB J. 2002;16:264-266.
27. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001;61:6050-6054.
28. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
29. Buchler P, Reber HA, Buchler MW, et al. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg. 2002;236:738-749; discussion 749.
30. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000; 88:2239-2245.
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. NEJM. 2004;350:2335-2342.
32. Gemcitiabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer. Cancer Biol Ther. 2007;6:137.
33. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumour associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther. 2003;2:1-7.
34. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93: 705-716.
35. Huang S-P, Wu M-S, Shun C-T, et al. Cyclooxygenase-2 increases hypoxia inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci. 2005;12:229-241.
36. von Rahden BH, Stein HJ, Puhringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 2005;65:5038-5044.
37. Eibl G, Bruemmer D, Okada Y, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306:887-897.
38. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
39. Eibl G, Takata Y, Boros L, et al. Growth stimulation of COX-2 negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res. 2005;65:982-990.
40. Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther. 2004;3:1217-1224.
41. Ueno T, Chow L, Toi M. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients. Biomed Pharmacother. 2006;60:277-279.
42. Jaffe E, Nachman R, Becker C, et al. Culture of human endothelial cells derived from umbilical veins. Identification of morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
43. Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402-408.
44. Murphy JF, Fitzgerald DJ. Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependant proliferation of endothelial cells (EC) via the VEGF-2 receptor. FASEB J. 2001;15: 1667-1669.
45. Murphy JF, Lennon F, Steele C, et al. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. FASEB J. 2005;19:446-448.
46. Murphy JF, Steele C, Belton O, et al. Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3. Br J Haematol. 2003;121:157-164.
47. Liu CH, Chang S-H, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumour genesis in transgenic mice. J Biol Chem. 2001;276:18563-18569.
48. Williams CS, Tsujii M, Resse J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589-1594.
49. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278: 35451-35457.
50. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23:254-266.
51. Buchler P, Reber HA, Ullrich A, et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery. 2003;134:772-782.
52. von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000;119: 1358-1372.
53. Wei D, Wang L, Yanjuan H, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 2004;64:2030-2038.